Israel - English - Ministry of Health

novartis israel ltd - mitoxantrone as hydrochloride - concentrate for solution for infusion - mitoxantrone as hydrochloride 2 mg/ml - mitoxantrone - mitoxantrone - treatment of advanced breast cancer, non-hodgkin's lymphomas, acute non lymphocytic leukemia palliation of non resectable primary hepatocellular carcinoma. mitoxantrone in combination with corticosterolds is indicated for inital chemotherapy in patients with pain due to advanced hormone-refractory prostate cancer. for reduction of neurologic disability and/or frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remmitting multiple sclerosis (patients whose neurologic status is significantly abnormal between relapses), for patients 18-55 years old.בקשה לשינוי התוויה: 5/1/2021mitoxantrone is indicated in the treatment of metastatic breast cancer.mitoxantrone is indicated in the treatment of non-hodgkin’s lymphoma.mitoxantrone is indicated for the treatment of acute myeloid leukaemia (aml) in adults.mitoxantrone in combination regimens is indicated in the remission-induction treatment of blast crisis in chronic myeloid leukaemia.mitoxantrone is indicated in combination with corticosteroids for palliation (e.g. pain relief) related to advanced castrate resistant prostate cancer.mitoxantrone is indicated for treatment of patients with highly active relapsing multiple sclerosis associated with rapidly evolving disability where no alternative therapeutic options exist.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - mitoxantrone hydrochloride (unii: u6usw86rd0) (mitoxantrone - unii:bz114nvm5p) - mitoxantrone 2 mg in 1 ml - mitoxantrone injection, usp is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). mitoxantrone injection, usp is not indicated in the treatment of patients with primary progressive multiple sclerosis. the clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability.  mitoxantrone injection, usp in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. mi

Canada - English - Health Canada

fresenius kabi canada ltd - mitoxantrone (mitoxantrone hydrochloride) - solution - 2mg - mitoxantrone (mitoxantrone hydrochloride) 2mg - antineoplastic agents

Canada - English - Health Canada

teva canada limited - mitoxantrone (mitoxantrone hydrochloride) - solution - 2mg - mitoxantrone (mitoxantrone hydrochloride) 2mg - antineoplastic agents

Canada - English - Health Canada

pfizer canada ulc - mitoxantrone (mitoxantrone hydrochloride) - solution - 2mg - mitoxantrone (mitoxantrone hydrochloride) 2mg - antineoplastic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - mitoxantrone hydrochloride 2.3284 mg/ml equivalent to mitoxantrone 2 mg/ml. australian approved name is mitozantrone hydrochloride. - solution for injection - 2 mg/ml - active: mitoxantrone hydrochloride 2.3284 mg/ml equivalent to mitoxantrone 2 mg/ml. australian approved name is mitozantrone hydrochloride. excipient: glacial acetic acid hydrochloric acid nitrogen sodium acetate sodium chloride sodium sulfate water for injection - mitozantrone ebewe is indicated for the treatment of: · metastatic carcinoma of the breast · non-hodgkin's lymphoma · adult acute non-lymphocytic leukaemia (anll) · chronic myelogenous leukaemia in blast crisis

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - mitoxantrone - concentrate for solution for infusion - 2 milligram(s)/millilitre - anthracyclines and related substances; mitoxantrone

Malta - English - Medicines Authority

accord healthcare limited - mitoxantrone - concentrate for solution for infusion - mitoxantrone 10 mg - antineoplastic agents

Malta - English - Medicines Authority

accord healthcare limited - mitoxantrone - concentrate for solution for infusion - mitoxantrone 20 mg - antineoplastic agents

Malta - English - Medicines Authority

accord healthcare limited - mitoxantrone - concentrate for solution for infusion - mitoxantrone 30 mg - antineoplastic agents